Taiwan Bio and TRACT Therapeutics Complete TregCel Tech Transfer

Taiwan Bio Therapeutics, Inc. and TRACT Therapeutics, Inc. have successfully completed the transfer of TRACT Therapeutics' TregCel platform technology to Taiwan Bio's GMP-certified cell manufacturing facility. This achievement marks a critical step forward in their preparation for a global Phase 2 clinical trial aimed at improving outcomes for living donor kidney transplant patients.

Cyrus Yang, CEO of Taiwan Bio Therapeutics, remarked, “We are extremely excited about the successful transfer of TRACT Therapeutics’ Treg cellular product to our facility. This achievement underscores our commitment to advancing cutting-edge cellular therapies and highlights our capabilities in high-quality cell therapy manufacturing. We look forward to supporting the upcoming Phase 2 clinical trial and the global manufacturing needs of this innovative cellular therapy. We are optimistic about the potential impact of this therapy on patients undergoing kidney transplants.”

The collaboration between the two companies, established in December 2023, combines Taiwan Bio's expertise in cellular therapy production with TRACT Therapeutics' pioneering TregCel platform, designed to modulate immune responses through regulatory T cell therapy.

The upcoming Phase 2 trial, set to take place in Taiwan and the United States, is based on the positive results of a Phase 1 study. The initial study showcased a strong safety profile and promising efficacy of TRACT's autologous Treg product, offering the potential to revolutionize treatment for transplant patients by reducing the dependency on traditional immunosuppressant therapies.

Dr. Joseph Leventhal, Scientific Founder of TRACT Therapeutics, further added, “This successful technology transfer represents a crucial step in our journey to bring our regulatory T cell therapy to patients in need. The collaboration with Taiwan Bio has been exceptional, and their manufacturing excellence aligns perfectly with our mission to develop transformative therapies. We are excited to continue our work towards improving outcomes and quality of life for transplant patients.”